首页 > 最新文献

Dermatologic Surgery最新文献

英文 中文
Deoxycholate for Subcutaneous Fat Reduction: A Review of Current Literature and Potential New Delivery Systems. 用于减少皮下脂肪的脱氧胆酸盐:现有文献综述和潜在的新给药系统
IF 2.5 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-02-04 DOI: 10.1097/DSS.0000000000004565
Rodrigo Moreira Caetano Pinto, Guilherme Moreira Caetano Pinto, Flávio Luís Beltrame, Priscileila Colerato Ferrari

Background: Deoxycholate is approved for submental fat reduction due to its ability to lyse cells and reduce fat accumulation, but it is used off-label in aesthetic treatments for subcutaneous fat reduction for several other parts of the body.

Objective: Review the clinical evidence supporting using sodium deoxycholate and delivery systems for aesthetic purposes.

Materials and methods: This systematic review explores the clinical evidence for sodium deoxycholate's efficacy and safety in fat reduction, exploring the use of delivery systems to mitigate adverse effects. A comprehensive literature search across Web of Science, Scopus, and PubMed was executed to prepare this review.

Results: Clinical studies confirm that subcutaneous deoxycholate injections effectively reduce submental fat, with long-term results suggesting maintained efficacy up to 3 years post-treatment. However, adverse effects are noted, prompting research into novel delivery systems, which include sustained-release liquid crystal formulations and micro/nanoparticle-based systems, promising to reduce side effects while enhancing efficacy.

Conclusion: The findings underscore that deoxycholate is clinically well-established in efficacy and safety, with substantial evidence for treating submental fat. More extensive clinical studies are necessary to establish its safety and effectiveness in larger treatment areas and optimize treatment outcomes using different delivery systems.

{"title":"Deoxycholate for Subcutaneous Fat Reduction: A Review of Current Literature and Potential New Delivery Systems.","authors":"Rodrigo Moreira Caetano Pinto, Guilherme Moreira Caetano Pinto, Flávio Luís Beltrame, Priscileila Colerato Ferrari","doi":"10.1097/DSS.0000000000004565","DOIUrl":"https://doi.org/10.1097/DSS.0000000000004565","url":null,"abstract":"<p><strong>Background: </strong>Deoxycholate is approved for submental fat reduction due to its ability to lyse cells and reduce fat accumulation, but it is used off-label in aesthetic treatments for subcutaneous fat reduction for several other parts of the body.</p><p><strong>Objective: </strong>Review the clinical evidence supporting using sodium deoxycholate and delivery systems for aesthetic purposes.</p><p><strong>Materials and methods: </strong>This systematic review explores the clinical evidence for sodium deoxycholate's efficacy and safety in fat reduction, exploring the use of delivery systems to mitigate adverse effects. A comprehensive literature search across Web of Science, Scopus, and PubMed was executed to prepare this review.</p><p><strong>Results: </strong>Clinical studies confirm that subcutaneous deoxycholate injections effectively reduce submental fat, with long-term results suggesting maintained efficacy up to 3 years post-treatment. However, adverse effects are noted, prompting research into novel delivery systems, which include sustained-release liquid crystal formulations and micro/nanoparticle-based systems, promising to reduce side effects while enhancing efficacy.</p><p><strong>Conclusion: </strong>The findings underscore that deoxycholate is clinically well-established in efficacy and safety, with substantial evidence for treating submental fat. More extensive clinical studies are necessary to establish its safety and effectiveness in larger treatment areas and optimize treatment outcomes using different delivery systems.</p>","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical Tranexamic Acid Application for Hidradenitis Suppurativa Procedures.
IF 2.5 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-02-03 DOI: 10.1097/DSS.0000000000004568
Nicholas D Flint, Mikael Horissian
{"title":"Topical Tranexamic Acid Application for Hidradenitis Suppurativa Procedures.","authors":"Nicholas D Flint, Mikael Horissian","doi":"10.1097/DSS.0000000000004568","DOIUrl":"https://doi.org/10.1097/DSS.0000000000004568","url":null,"abstract":"","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated Review of Cellular Dermatofibroma: Benign or Not?
IF 2.5 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-02-03 DOI: 10.1097/DSS.0000000000004554
Nicholas T Le, Maxwell A Fung, Daniel B Eisen

Background: Cellular dermatofibromas (CDFs) are uncommon benign fibrous histiocytomas with histologic patterns resembling malignancies. Despite their benign nature, CDFs can recur and metastasize. Physicians are uncertain about the management of CDF, given its resemblance to dermatofibrosarcoma protuberans.

Objective: This review aims to review CDF's clinical and histologic features, differentiate it from similar presenting malignancies, and discuss treatments and outcomes for better clinical management.

Materials and methods: In April 2024, a PubMed and Google Scholar search was completed using "cellular dermatofibroma" through the University of California Davis Medical School's library databases. The search included meta-analyses, randomized controlled trials, observational studies, reviews, and case studies published within the past 70 years. References from retrieved articles were utilized as additional resources.

Results: Clinical signs of CDF include firm, skin-colored to hyperpigmented lesions usually larger than 2 cm, typically on extremities. Currently, there are no definitive indicators for CDF recurrence or metastasis. Diagnosis requires microscopic and histopathologic examination, with surgical excision as the preferred treatment. Recurrence is not uncommon, while metastasis is rare.

Conclusion: CDFs often develop in young/middle-aged adults with a tendency to recur and in rare cases can metastasize. Future studies could explore lesion characteristics that are associated with potential for recurrence and metastasis.

{"title":"Updated Review of Cellular Dermatofibroma: Benign or Not?","authors":"Nicholas T Le, Maxwell A Fung, Daniel B Eisen","doi":"10.1097/DSS.0000000000004554","DOIUrl":"https://doi.org/10.1097/DSS.0000000000004554","url":null,"abstract":"<p><strong>Background: </strong>Cellular dermatofibromas (CDFs) are uncommon benign fibrous histiocytomas with histologic patterns resembling malignancies. Despite their benign nature, CDFs can recur and metastasize. Physicians are uncertain about the management of CDF, given its resemblance to dermatofibrosarcoma protuberans.</p><p><strong>Objective: </strong>This review aims to review CDF's clinical and histologic features, differentiate it from similar presenting malignancies, and discuss treatments and outcomes for better clinical management.</p><p><strong>Materials and methods: </strong>In April 2024, a PubMed and Google Scholar search was completed using \"cellular dermatofibroma\" through the University of California Davis Medical School's library databases. The search included meta-analyses, randomized controlled trials, observational studies, reviews, and case studies published within the past 70 years. References from retrieved articles were utilized as additional resources.</p><p><strong>Results: </strong>Clinical signs of CDF include firm, skin-colored to hyperpigmented lesions usually larger than 2 cm, typically on extremities. Currently, there are no definitive indicators for CDF recurrence or metastasis. Diagnosis requires microscopic and histopathologic examination, with surgical excision as the preferred treatment. Recurrence is not uncommon, while metastasis is rare.</p><p><strong>Conclusion: </strong>CDFs often develop in young/middle-aged adults with a tendency to recur and in rare cases can metastasize. Future studies could explore lesion characteristics that are associated with potential for recurrence and metastasis.</p>","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Large Percentage of Excision Specimens Show Residual Basal Cell Carcinoma: A Retrospective Chart Review. 大量切除标本显示残留基底细胞癌:回顾性病历分析
IF 2.5 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-02-01 Epub Date: 2024-09-16 DOI: 10.1097/DSS.0000000000004399
Ariana J Cecil, Spencer P McClure, Edward W Seger, Nasrin Sultana, Jesalyn A Tate

Background: Treatment of basal cell carcinoma (BCC) is recommended. However, patients often note that the biopsy site appears resolved and inquire about the need for additional treatment.

Objective: This study aims to determine the rate of residual BCC on excision specimens after initial shave biopsy to aid in decision-making on the necessity of further treatment.

Methods and materials: A retrospective chart review was conducted that reviewed excision specimen pathology reports of previously biopsy-proven basal cell carcinomas for the presence of residual tumor between 2012 and 2022 at a single institution.

Results: Two thousand one hundred seventeen cases met inclusion criteria. Overall, 39.4% of patients had residual BCC after an initial shave biopsy. Using an odds ratio and 95% confidence interval, a significant relationship was found between larger lesions, longer time between biopsy and excision, and lesions on high-risk body sites with increased odds of residual BCC. A significant relationship was found between negative or not specified margins on shave biopsy with decreased odds of residual BCC.

Conclusion: The results show that a large percentage of patients have residual BCC following initial biopsies. These results should be included in physician-patient discussions about treatment options for BCC.

背景:建议对基底细胞癌(BCC)进行治疗。然而,患者往往会注意到活检部位似乎已经愈合,并询问是否需要进行额外治疗:本研究旨在确定初次剃须活检后切除标本上残留 BCC 的比率,以帮助决定是否需要进一步治疗:研究人员进行了一项回顾性病历审查,审查了一家医疗机构2012年至2022年间通过活检证实的基底细胞癌切除标本病理报告,以确定是否存在残留肿瘤:符合纳入标准的病例有 217 例。总体而言,39.4%的患者在初次剃须活检后有BCC残留。通过几率比和95%置信区间,发现病变面积较大、活检与切除之间的间隔时间较长以及病变位于高风险身体部位与残留BCC几率增加之间存在显著关系。剃须活检边缘阴性或未指定边缘与残留 BCC 的几率降低之间存在明显关系:结论:研究结果表明,很大一部分患者在初次活检后有残留 BCC。这些结果应纳入医患关于 BCC 治疗方案的讨论中。
{"title":"A Large Percentage of Excision Specimens Show Residual Basal Cell Carcinoma: A Retrospective Chart Review.","authors":"Ariana J Cecil, Spencer P McClure, Edward W Seger, Nasrin Sultana, Jesalyn A Tate","doi":"10.1097/DSS.0000000000004399","DOIUrl":"10.1097/DSS.0000000000004399","url":null,"abstract":"<p><strong>Background: </strong>Treatment of basal cell carcinoma (BCC) is recommended. However, patients often note that the biopsy site appears resolved and inquire about the need for additional treatment.</p><p><strong>Objective: </strong>This study aims to determine the rate of residual BCC on excision specimens after initial shave biopsy to aid in decision-making on the necessity of further treatment.</p><p><strong>Methods and materials: </strong>A retrospective chart review was conducted that reviewed excision specimen pathology reports of previously biopsy-proven basal cell carcinomas for the presence of residual tumor between 2012 and 2022 at a single institution.</p><p><strong>Results: </strong>Two thousand one hundred seventeen cases met inclusion criteria. Overall, 39.4% of patients had residual BCC after an initial shave biopsy. Using an odds ratio and 95% confidence interval, a significant relationship was found between larger lesions, longer time between biopsy and excision, and lesions on high-risk body sites with increased odds of residual BCC. A significant relationship was found between negative or not specified margins on shave biopsy with decreased odds of residual BCC.</p><p><strong>Conclusion: </strong>The results show that a large percentage of patients have residual BCC following initial biopsies. These results should be included in physician-patient discussions about treatment options for BCC.</p>","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":"134-138"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using Neuromodulators for Salivary, Eccrine, and Apocrine Gland Disorders: Erratum. 使用神经调节剂治疗唾液腺、泪腺和分泌腺疾病:勘误。
IF 2.5 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-02-01 Epub Date: 2024-12-16 DOI: 10.1097/DSS.0000000000004517
Susruthi Rajanala, Nicole Salame, Jeffrey S Dover
{"title":"Using Neuromodulators for Salivary, Eccrine, and Apocrine Gland Disorders: Erratum.","authors":"Susruthi Rajanala, Nicole Salame, Jeffrey S Dover","doi":"10.1097/DSS.0000000000004517","DOIUrl":"10.1097/DSS.0000000000004517","url":null,"abstract":"","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":"229"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The History and Advancement of Light, Lasers, and Energy-Based Devices in Dermatologic Surgery.
IF 2.5 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-02-01 DOI: 10.1097/DSS.0000000000004542
Jeffrey S Dover, Chaocheng Liu, Jacqueline Watchmaker, Jordan V Wang, Roy G Geronemus, Kenneth A Arndt, R Rox Anderson

Background: From the theoretical foundations of laser and energy-based applications for the skin to the development of advanced medical devices, the field of dermatologic surgery has undergone transformative changes.

Objective: To review the scientific and clinical advancement of laser and energy-based therapies within dermatologic surgery.

Materials and methods: A literature search was conducted to identify important scientific advancements and landmark studies on light, laser, and energy-based devices within the field of dermatologic surgery.

Results: Since the introduction of selective photothermolysis principles in the 1980s, numerous laser and energy-based devices have been developed to effectively treat vascular lesions, target pigmentation, remove tattoos, rejuvenate the skin, and remove hair. Beyond aesthetic applications, photodynamic therapy was introduced to treat various neoplastic and inflammatory conditions. Lasers have also been employed to enhance transcutaneous drug delivery, and new lasers continue to emerge for treating common inflammatory conditions, such as acne. These innovations have contributed to a paradigm shift toward safe and effective, but less invasive, procedure-based treatment in addressing medical and aesthetic concerns in dermatology.

Conclusion: Dermatologists have consistently led the way in the continuous development and innovative application of laser and energy-based devices to effectively address a variety of skin conditions.

{"title":"The History and Advancement of Light, Lasers, and Energy-Based Devices in Dermatologic Surgery.","authors":"Jeffrey S Dover, Chaocheng Liu, Jacqueline Watchmaker, Jordan V Wang, Roy G Geronemus, Kenneth A Arndt, R Rox Anderson","doi":"10.1097/DSS.0000000000004542","DOIUrl":"10.1097/DSS.0000000000004542","url":null,"abstract":"<p><strong>Background: </strong>From the theoretical foundations of laser and energy-based applications for the skin to the development of advanced medical devices, the field of dermatologic surgery has undergone transformative changes.</p><p><strong>Objective: </strong>To review the scientific and clinical advancement of laser and energy-based therapies within dermatologic surgery.</p><p><strong>Materials and methods: </strong>A literature search was conducted to identify important scientific advancements and landmark studies on light, laser, and energy-based devices within the field of dermatologic surgery.</p><p><strong>Results: </strong>Since the introduction of selective photothermolysis principles in the 1980s, numerous laser and energy-based devices have been developed to effectively treat vascular lesions, target pigmentation, remove tattoos, rejuvenate the skin, and remove hair. Beyond aesthetic applications, photodynamic therapy was introduced to treat various neoplastic and inflammatory conditions. Lasers have also been employed to enhance transcutaneous drug delivery, and new lasers continue to emerge for treating common inflammatory conditions, such as acne. These innovations have contributed to a paradigm shift toward safe and effective, but less invasive, procedure-based treatment in addressing medical and aesthetic concerns in dermatology.</p><p><strong>Conclusion: </strong>Dermatologists have consistently led the way in the continuous development and innovative application of laser and energy-based devices to effectively address a variety of skin conditions.</p>","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":"113-122"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low-Level Laser and LED Therapy in Alopecia: A Systematic Review and Meta-Analysis. 低强度激光和 LED 治疗脱发:系统回顾与元分析》。
IF 2.5 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-02-01 Epub Date: 2024-10-15 DOI: 10.1097/DSS.0000000000004442
Sofia M Perez, Mounika Vattigunta, Colin Kelly, Ariel Eber

Background: Low-level laser/LED therapy (LLLT) has been described as a treatment option for alopecia, but no study has comprehensively reviewed its efficacy in multiple alopecia types.

Objective: To review and evaluate LLLT for various alopecia types.

Materials and methods: A systematic search of PubMed/MEDLINE, Embase, and CENTRAL was conducted to identify studies assessing the effect of LLLT on patients diagnosed with alopecia. Prespecified outcome measure was the change in hair density. Meta-analysis was performed to calculate the standardized mean difference in hair density before and after LLLT compared with placebo.

Results: Thirty-eight studies were included that described 3,098 patients with androgenetic alopecia (2,930/3,098), scarring alopecia (49/3,098), alopecia areata (50/3,098), telogen effluvium (17/3,098), and chemotherapy-induced alopecia (32/3,098). The mean change in hair density increased significantly in androgenetic alopecia patients after LLLT for 4 to 26 weeks compared with placebo (<20 weeks: SMD = 1.14; 95% CI [0.51-1.78]; p = .000; I 2 = 88.26%; >20 weeks: SMD = 1.44; 95% CI [0.97-1.91]; p = .000; I 2 = 80.81%). Change in hair density was reported in 5 studies evaluating other alopecia types; however, statistical information was insufficient for meta-analysis.

Conclusion: LLLT is a promising treatment option for patients with androgenetic alopecia, but future studies are needed to better understand its efficacy in other alopecia types.

背景:低强度激光/LED疗法(LLLT)已被描述为治疗脱发的一种选择,但还没有研究对其在多种脱发类型中的疗效进行全面评估:回顾并评估 LLLT 治疗各种类型脱发的效果:对 PubMed/MEDLINE、Embase 和 CENTRAL 进行了系统检索,以确定评估 LLLT 对确诊脱发患者疗效的研究。预设的结果测量指标为毛发密度的变化。通过进行 Meta 分析,计算出 LLLT 治疗前后头发密度与安慰剂相比的标准化平均差异:结果:共纳入了 38 项研究,这些研究描述了 3098 名雄激素性脱发患者(2930 人/3098 人)、瘢痕性脱发患者(49 人/3098 人)、斑秃患者(50 人/3098 人)、毛发脱落症患者(17 人/3098 人)以及化疗引起的脱发患者(32 人/3098 人)。与安慰剂相比,雄激素性脱发患者在接受 LLLT 治疗 4 到 26 周后,头发密度的平均变化明显增加(20 周:SMD = 1.44;95% CI [0.97-1.91];p = .000;I2 = 80.81%)。5项评估其他脱发类型的研究报告了头发密度的变化,但统计信息不足以进行荟萃分析:结论:对于雄激素性脱发患者来说,LLLT 是一种很有前景的治疗方法,但还需要进行更多研究,以更好地了解它对其他类型脱发的疗效。
{"title":"Low-Level Laser and LED Therapy in Alopecia: A Systematic Review and Meta-Analysis.","authors":"Sofia M Perez, Mounika Vattigunta, Colin Kelly, Ariel Eber","doi":"10.1097/DSS.0000000000004442","DOIUrl":"10.1097/DSS.0000000000004442","url":null,"abstract":"<p><strong>Background: </strong>Low-level laser/LED therapy (LLLT) has been described as a treatment option for alopecia, but no study has comprehensively reviewed its efficacy in multiple alopecia types.</p><p><strong>Objective: </strong>To review and evaluate LLLT for various alopecia types.</p><p><strong>Materials and methods: </strong>A systematic search of PubMed/MEDLINE, Embase, and CENTRAL was conducted to identify studies assessing the effect of LLLT on patients diagnosed with alopecia. Prespecified outcome measure was the change in hair density. Meta-analysis was performed to calculate the standardized mean difference in hair density before and after LLLT compared with placebo.</p><p><strong>Results: </strong>Thirty-eight studies were included that described 3,098 patients with androgenetic alopecia (2,930/3,098), scarring alopecia (49/3,098), alopecia areata (50/3,098), telogen effluvium (17/3,098), and chemotherapy-induced alopecia (32/3,098). The mean change in hair density increased significantly in androgenetic alopecia patients after LLLT for 4 to 26 weeks compared with placebo (<20 weeks: SMD = 1.14; 95% CI [0.51-1.78]; p = .000; I 2 = 88.26%; >20 weeks: SMD = 1.44; 95% CI [0.97-1.91]; p = .000; I 2 = 80.81%). Change in hair density was reported in 5 studies evaluating other alopecia types; however, statistical information was insufficient for meta-analysis.</p><p><strong>Conclusion: </strong>LLLT is a promising treatment option for patients with androgenetic alopecia, but future studies are needed to better understand its efficacy in other alopecia types.</p>","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":"179-183"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunohistochemistry-Assisted Mohs Surgery for Invasive Eyelid and Periorbital Cutaneous Melanoma. 免疫组化辅助莫氏手术治疗侵袭性眼睑和眶周皮肤黑色素瘤。
IF 2.5 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-02-01 Epub Date: 2024-10-23 DOI: 10.1097/DSS.0000000000004423
Eucabeth M Asamoah, Addison M Demer, Thomas E Trischman, Anagha Bangalore Kumar, Nahid Y Vidal, Lilly H Wagner

Background: Prior studies describe wide local excision and "slow Mohs" outcomes for periocular melanoma. Mohs micrographic surgery (MMS) with immunohistochemistry maximizes tissue preservation and offers same-day comprehensive margin evaluation, which facilitates expedited repair, and coordination of oculoplastic reconstruction when necessary.

Objective: To describe oncologic and reconstructive outcomes of invasive periocular cutaneous melanoma treated with immunohistochemistry-assisted MMS.

Materials and methods: Invasive melanoma cases affecting the eyelids or periorbital region treated with MMS between 2008 and 2018 were reviewed. Eyelid tumors and those in adjacent subunits were compared. Main outcome measures were recurrence, melanoma-specific death, and postreconstructive complications.

Results: Of 42 cases, 28 were classified as periorbital and 14 as eyelid involving. Most were T1 (37, 88.1%). There was 1 local recurrence in a patient with persistent positive conjunctival margin (2.4%). No local recurrences were observed in cases where negative Mohs margins were achieved, and no melanoma-related deaths occurred. Eyelid tumors were more likely to result in lid margin involving defects and require oculoplastic reconstruction. Eyelid complications developed in 10 cases (23.8%), and 5 (11.9%) required revision surgery.

Conclusion: Mohs micrographic surgery for periocular melanoma results in low rates of local recurrence and melanoma-specific death. Initial tumor location can aid in reconstructive planning.

背景:先前的研究描述了眼周黑色素瘤的广泛局部切除和 "慢莫尔斯 "结果。采用免疫组化技术的莫氏显微放射手术(MMS)可最大限度地保留组织,并在当天对边缘进行全面评估,从而加快修复速度,并在必要时协调眼部整形重建:描述采用免疫组化辅助 MMS 治疗的侵袭性眼周皮肤黑色素瘤的肿瘤学和重建结果:回顾2008年至2018年期间采用MMS治疗的眼睑或眶周侵袭性黑色素瘤病例。比较了眼睑肿瘤和邻近亚单位的肿瘤。主要结果指标为复发、黑色素瘤特异性死亡和复发后并发症:在42例病例中,28例被归类为眶周肿瘤,14例被归类为眼睑肿瘤。大多数为T1(37例,88.1%)。一名结膜边缘持续阳性的患者出现了局部复发(2.4%)。在莫氏切缘阴性的病例中未发现局部复发,也没有黑色素瘤相关死亡病例。眼睑肿瘤更有可能导致睑缘缺损,需要进行眼部整形。10例(23.8%)患者出现眼睑并发症,5例(11.9%)需要进行翻修手术:莫氏显微放射手术治疗眼周黑色素瘤的局部复发率和黑色素瘤特异性死亡率都很低。最初的肿瘤位置有助于制定重建计划。
{"title":"Immunohistochemistry-Assisted Mohs Surgery for Invasive Eyelid and Periorbital Cutaneous Melanoma.","authors":"Eucabeth M Asamoah, Addison M Demer, Thomas E Trischman, Anagha Bangalore Kumar, Nahid Y Vidal, Lilly H Wagner","doi":"10.1097/DSS.0000000000004423","DOIUrl":"10.1097/DSS.0000000000004423","url":null,"abstract":"<p><strong>Background: </strong>Prior studies describe wide local excision and \"slow Mohs\" outcomes for periocular melanoma. Mohs micrographic surgery (MMS) with immunohistochemistry maximizes tissue preservation and offers same-day comprehensive margin evaluation, which facilitates expedited repair, and coordination of oculoplastic reconstruction when necessary.</p><p><strong>Objective: </strong>To describe oncologic and reconstructive outcomes of invasive periocular cutaneous melanoma treated with immunohistochemistry-assisted MMS.</p><p><strong>Materials and methods: </strong>Invasive melanoma cases affecting the eyelids or periorbital region treated with MMS between 2008 and 2018 were reviewed. Eyelid tumors and those in adjacent subunits were compared. Main outcome measures were recurrence, melanoma-specific death, and postreconstructive complications.</p><p><strong>Results: </strong>Of 42 cases, 28 were classified as periorbital and 14 as eyelid involving. Most were T1 (37, 88.1%). There was 1 local recurrence in a patient with persistent positive conjunctival margin (2.4%). No local recurrences were observed in cases where negative Mohs margins were achieved, and no melanoma-related deaths occurred. Eyelid tumors were more likely to result in lid margin involving defects and require oculoplastic reconstruction. Eyelid complications developed in 10 cases (23.8%), and 5 (11.9%) required revision surgery.</p><p><strong>Conclusion: </strong>Mohs micrographic surgery for periocular melanoma results in low rates of local recurrence and melanoma-specific death. Initial tumor location can aid in reconstructive planning.</p>","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":"127-133"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reporting Rates of Chemoprevention Agent Use in Individuals With Cutaneous Field Cancerization. 报告皮肤野癌患者使用化学预防药物的比例。
IF 2.5 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-02-01 Epub Date: 2024-09-05 DOI: 10.1097/DSS.0000000000004394
Katherine Plampton, Bo Kitrell, Ashley Wysong, Adam Sutton
{"title":"Reporting Rates of Chemoprevention Agent Use in Individuals With Cutaneous Field Cancerization.","authors":"Katherine Plampton, Bo Kitrell, Ashley Wysong, Adam Sutton","doi":"10.1097/DSS.0000000000004394","DOIUrl":"10.1097/DSS.0000000000004394","url":null,"abstract":"","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":"200-201"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Retrospective Review of the Frequency of Incomplete Excision and Upstaging of Early-Stage Melanomas at a Single Academic Institution. 对一家学术机构早期黑色素瘤不完全切除和上行分期发生率的回顾性研究。
IF 2.5 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-02-01 Epub Date: 2024-09-30 DOI: 10.1097/DSS.0000000000004408
Stephanie von Csiky-Sessoms, Sumanth Chennareddy, Ryan Rivera-Oyola, George Niedt, Jesse M Lewin
{"title":"A Retrospective Review of the Frequency of Incomplete Excision and Upstaging of Early-Stage Melanomas at a Single Academic Institution.","authors":"Stephanie von Csiky-Sessoms, Sumanth Chennareddy, Ryan Rivera-Oyola, George Niedt, Jesse M Lewin","doi":"10.1097/DSS.0000000000004408","DOIUrl":"10.1097/DSS.0000000000004408","url":null,"abstract":"","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":"208-209"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Dermatologic Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1